Open AccessThe Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies
Author(s) -
David T. Rubin,
Jenny Griffith,
Qisu Zhang,
Zsolt Hepp,
Allison Keshishian
Publication year - 2020
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izaa270
Subject(s) - medicine , inflammatory bowel disease , ulcerative colitis , disease , tumor necrosis factor alpha , crohn's disease , complication , infliximab , fistula , gastroenterology , intensive care medicine , surgery
Although there is evidence that anti-tumor necrosis factor (TNF) utilization earlier in the inflammatory bowel disease (IBD) course and before the onset of disease-related complications leads to improved patient outcomes, the health care costs and utilization impact have not been well defined. This study assessed differences in health care utilization and costs among patients with IBD treated with anti-TNFs.